Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial

scientific article published on January 2010

Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3851/IMP1695
P698PubMed publication ID21149918
P5875ResearchGate publication ID49675735

P50authorPeter MugyenyiQ16732954
Victor MusiimeQ43093872
Margaret ThomasonQ56547049
Sabrina Bakeera-KitakaQ60249119
Diana M GibbQ62738885
Lindsay KendallQ63630847
Ann Sarah WalkerQ90248231
Philippa MusokeQ96163738
ARROW Trial teamQ114437775
P2093author name stringDavid Burger
Adeodata Kekitiinwa
Kimberly Adkison
Florence Odongo
Wendy B Snowden
P433issue8
P921main subjectUgandaQ1036
abacavirQ304330
pharmacokineticsQ323936
lamivudineQ422631
P304page(s)1115-1124
P577publication date2010-01-01
P1433published inAntiviral TherapyQ4775353
P1476titlePharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial
P478volume15

Reverse relations

cites work (P2860)
Q38723580Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis
Q37866289Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges
Q37731863Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children
Q38771392Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.
Q36306986Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial
Q42905874Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research
Q37696578Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials
Q36386846Managing HIV-infected children in a low-resource, public clinic: a comparison of nurse vs. clinical officer practices in ART refill, calculation of adherence and subsequent appointments.
Q38855053Once vs twice-daily abacavir and lamivudine in African children
Q41505058Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life
Q38868724Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.
Q37708677Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children
Q37098376Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children
Q36948138Population pharmacokinetics of abacavir in infants, toddlers and children
Q30539434Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial
Q44986291When to start, what to start and other treatment controversies in pediatric HIV infection
Q28483158Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa

Search more.